Delivering Unprecedented Access to Biosimilars in Global Markets
  • Developing, Manufacturing and Commercializing
    Biosimilar Products for Global Markets
Who We Are

Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Epirus’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Learn More

News & Events

November 17, 2014

Data from EPIRUS' Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting

November 10, 2014

EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update

Bookmark and Share